LCTX

Business Context and Reporting Period

Company: BioTime, Inc. (Note: Input metadata referenced "Lineage Cell Therapeutics," but the filing text identifies the registrant as BioTime, Inc.)
Reporting Period: Quarterly period ended September 30, 2004 (Form 10-Q).
Business Stage: Development stage company engaged in the research and development of synthetic plasma expanders (Hextend, PentaLyte) and organ preservation solutions (HetaCool). The company has incurred cumulative net losses of $37.9 million since inception.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue for the three months ended September 30, 2004, increased to $170,381 from $109,870 in the same period in 2003. Royalty revenue from Hospira (successor to Abbott) increased 52% to $145,208, driven by higher sales to the U.S. Armed Forces and hospitals.
• Profitability: The company reported a net loss of $452,060 for the quarter, compared to a net income of $362,020 in the prior year quarter. The prior year income was significantly boosted by a $1 million life insurance payout following the death of a former CEO, which did not recur.
• Debt Elimination: In February 2004, the company eliminated all $3.35 million in debenture indebtedness. This was achieved by repaying $1.85 million in cash and converting $1.5 million of debt into common shares and warrants. Consequently, interest expense dropped significantly compared to the prior year.
• Expense Increases: Research and development (R&D) expenses rose to $305,626 (Q3 2004) from $239,760 (Q3 2003), primarily due to increased consultant fees and outside research costs. General and administrative expenses also increased due to higher legal and investor relations fees.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes existing cash ($1.57 million) and anticipated royalties are sufficient to fund operations through June 30, 2005. The company explicitly states it needs additional capital to continue operations and complete clinical trials.
• Product Development:
  • Hextend: Commercially launched; sales are in a ramp-up phase. Royalties are the primary revenue source.
  • PentaLyte: Phase I clinical trials completed; Phase II trials are planned with an estimated cost of $1 million. Regulatory approval in the U.S. may take longer than Hextend due to the use of pentastarch.
  • HetaCool: Development for low-temperature surgery. The company was awarded an NIH grant of up to $300,000, though no funds had been received as of the filing date.
• Risks:
  • Capital Needs: Unavailability of additional financing could force the company to curtail or discontinue operations.
  • Regulatory Approval: Success depends on FDA and foreign regulatory approvals for PentaLyte and HetaCool.
  • Revenue Timing: Royalty revenues are recognized when sales reports are received (often with a lag), making quarterly revenue volatile and difficult to predict.

Investor Verification Checklist

• Cash Runway: Verify if the company has secured additional financing since the filing to extend operations beyond the projected June 30, 2005 date.
• Royalty Collections: Confirm the receipt of Q3 2004 royalties (reported as $147,148 received in October 2004) and subsequent quarters to ensure Hospira sales remain robust.
• Clinical Trial Progress: Monitor the status and cost of the Phase II clinical trials for PentaLyte, as delays could increase capital requirements.
• Equity Dilution: Review any new equity issuances, as the company has a history of raising capital through rights offers and share sales, which dilutes existing shareholders.
• License Agreements: Track the status of the CJ Corp. agreement in South Korea, specifically regarding regulatory pricing approval required before sales can commence.